Clinical efficacy of Modified Gengnianchun Formula (Bushen Shugan Huoxue formula) combined with artificial cycle of western medicine on Stress-Induced Diminished Ovarian Reserve

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400079652

Enrollment

Unknown

Registered

2024-01-08

Start date

2024-01-08

Completion date

Unknown

Last updated

2024-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diminished ovarian reserve

Interventions

Traditional Chinese medicine group:Oral Modified Gengnianchun Formula (MGNC)

Western medicine artificial cycle group:Oral estradiol valerate + dydrogesterone

Integrated traditional Chinese and western medicine group:Oral Modified Gengnianchun Formula (MGNC) and estradiol valerate + dydrogesterone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ? Age of 18-40 years old; ? In accordance with DOR western medicine diagnosis and TCM syndrome differentiation criteria of kidney deficiency and liver depression; ? those who voluntarily participated in this study and signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) patients with known or suspected serious primary diseases of cardiovascular and cerebrovascular, liver, kidney, hematopoietic system, and mental illness; (2) patients with congenital or acquired organic diseases of the reproductive system and menstrual disorders caused by other endocrine factors (such as hyperprolactinemia, polycystic ovary syndrome) Syndrome, abnormal thyroid function, etc.). ? known or suspected breast cancer or sex hormone-dependent cancer; ? unexplained vaginal bleeding and untreated abnormal endometrial hyperplasia; ? patients with active venous or arterial thromboembolic disease in the past 6 months; ? suspected or real history of smoking, alcohol or drug abuse; ? Known or suspected pregnant or lactating women; ? Patients treated with estrogen, progesterone and related traditional Chinese medicine in the past 3 months, or participating in other clinical trials; ? Those who had allergic reactions before the study medication;

Design outcomes

Primary

Measure	Time frame
Follicle stimulating hormone;	—

Secondary

Measure	Time frame
Luteinizing hormone;Estrogen;Androgen;Anti-mullerian hormone;Cortisol;Antral follicle number;Chinese medicine symptom complex score;Self-rating anxiety Scale;Self-rating depression Scale;	—

Countries

China

Contacts

Public ContactRao yanqiu

Obstetrics and Gynecology Hospital of Fudan University

yanqiu022@163.com+86 137 8897 0776

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026